Pulse Biosciences, Inc. (PLSE) Balance Sheet

The balance sheet has strengthened dramatically over the past two years, with total assets rising from $40.4M to $115.6M, primarily due to cash infusions from financing activities. This suggests the company is well-capitalized for its current burn rate, but the reliance on external funding rather than operational cash flow indicates a continued dependence on investor support.

The company's debt-to-equity ratio has fallen from 0.32 in 2024Q2 to 0.07, reflecting both equity raises and modest debt repayment. While leverage is low, the absolute debt level of $6.8M is not trivial relative to cash, and investors should monitor refinancing terms given the company's negative cash flow.

The asset base is dominated by cash and short-term investments, with net PP&E shrinking as a percentage of total assets, now at 5.5%. Goodwill is stable at $2.8M, suggesting no acquisition-driven impairment concerns, but the declining PP&E may indicate limited investment in fixed assets, consistent with an outsourced manufacturing approach.

The equity base has expanded significantly, but this is entirely due to capital raises, as accumulated deficits continue to grow. The company has not generated retained earnings, and the negative retained earnings balance underscores the ongoing losses. Shareholders should be aware of potential dilution from future financing rounds.

Liquidity is strong on a static basis, with a current ratio above 9, but the company's cash burn is accelerating, with operating cash outflows averaging over $25M per quarter. At the current burn rate, the cash balance provides a runway of approximately 3-4 quarters, suggesting a need for additional funding within the next year unless revenue growth accelerates.